- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
New General Manager for Lilly UK, Ireland and Northern Europe
Laura Steele will lead Lilly’s commercial business operations in six countries, across the company’s current and emerging portfolio in Diabetes, Oncology, Immunology and Neuroscience.
Eli Lilly & Company announced that Laura Steele has been appointed President and General Manager (GM) for UK, Ireland & Northern Europe.
Steele will lead Lilly’s commercial business operations in six countries, across the company’s current and emerging portfolio in Diabetes, Oncology, Immunology and Neuroscience. She brings 18 years’ experience with the company to her new role, and joins from Lilly’s Corporate Business Development division, where she specialized in innovation partnerships, large-scale projects in M&A, investments and joint ventures, to drive growth across the company.
Laura Steele
“As we emerge from the COVID-19 pandemic, we must build on what we have learned during this crisis. From accelerating the set-up of new clinical trials to advances in delivering care outside of traditional settings, and combating health inequalities, the partnership and advances in care created during the pandemic must not be lost," Steele commented.
Steele succeeds Ashley Diaz-Granados, who assumes a senior role within Lilly USA leading the company’s Immunology division.
Fierce Females in the Life Science Space
March 29th 2024In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.
FDA Approves Roche’s Alecensa as Adjuvant Treatment for ALK-Positive Early-Stage NSCLC
April 19th 2024Data from the Phase III ALINA trial show that Alecensa reduced the risk of disease recurrence or death by 76% vs. platinum-based chemotherapy in patients with completely resected IB to IIIA ALK-positive non–small cell lung cancer.
